Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Trileptal (oxcarbazepine) tablets and suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011

 

Summary View

 

PRECAUTIONS

Changes to Multi-Organ Hypersensitivity subsection
Hematologic Events
  • Rare reports of pancytopenia, agranulocytosis, and leukopenia have been seen in patients treated with Trileptal during post-marketing experience. Discontinuation of the drug should be considered if any evidence of these hematologic events develop.
Pregnancy/Special Populations
  • adds information regarding pharmacokinetics during pregnancy
Drug Interactions
  • add cyclosporine to the list of drugs that have reduced plasma levels

ADVERSE REACTIONS

Postmarketing
  • Hemic and Lymphatic System - Bone marrow depression, agranulocytosis, aplastic anemia, pancytopenia, neutropenia"
  • Pancreatitis and/or lipase and/or amylase increase
  • Metabolism and Nutrition Disorders - Folic Acid Deficiency
-
-